No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alemtuzumab / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Betacoronavirus
-
COVID-19
-
Chile / epidemiology
-
Coronavirus Infections / epidemiology
-
Decision Making
-
Female
-
Fingolimod Hydrochloride / therapeutic use
-
Glatiramer Acetate / therapeutic use
-
Guideline Adherence
-
Guidelines as Topic
-
Health Behavior*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Interferons / therapeutic use
-
Lymphocyte Count
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis, Chronic Progressive / drug therapy
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Natalizumab / therapeutic use
-
Pandemics
-
Pneumonia, Viral / epidemiology
-
Quarantine*
-
SARS-CoV-2
-
World Health Organization
-
Young Adult
Substances
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
Natalizumab
-
Alemtuzumab
-
Glatiramer Acetate
-
Interferons
-
ocrelizumab
-
Fingolimod Hydrochloride